UNSPSC 51202416: Daratumumab

A CD38-directed cytolytic antibody.

UNSPSC 51202416 Daratumumab is a Commodity code that encompasses pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged with this code show limited direct activity for daratumumab specifically and instead reflect broader pharmaceutical procurement patterns across multiple drug categories and delivery models. State and local buyers use this code and related pharmaceutical categories to source generic multi-source drugs, over-the-counter products, specialty pharmaceuticals, and emergency medical supplies through cooperative purchasing vehicles, direct manufacturer relationships, and traditional competitive bidding. Issuing bodies range from state health and human services commissions and cooperative purchasing alliances to county health departments and municipal fire/rescue divisions, with recent activity concentrated in Florida, Texas, and Minnesota through entities including Seminole County, the Texas Health and Human Services Commission, the City of Tampa, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP).

Recent opportunities reflect diverse procurement models: Seminole County, Florida issued an IFB (due July 26, 2023) for naloxone and drug deactivation systems; the Texas HHS Commission issued a Request for Information (April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels; the City of Tampa issued a sheltered-market IFB (due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000 with a 5 percent small local business enterprise discount; and MMCAP issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and meet FDA and Drug Supply Chain Security Act compliance. The geographic spread across Florida, Texas, Minnesota, and Oregon suggests multi-state cooperative purchasing drives a significant portion of pharmaceutical procurement activity at the state and local level.